Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

GCN2 activator

DRUG CLASS:

GCN2 activator

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

›

ARID1A mutation	Ovarian Cancer	ARID1A mutation	Ovarian Cancer	NXP800 Sensitive: B - Late Trials NXP800 Sensitive : B	NXP800 Sensitive: B - Late Trials NXP800 Sensitive : B
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	HC-7366 Sensitive: B - Late Trials HC-7366 Sensitive : B	HC-7366 Sensitive: B - Late Trials HC-7366 Sensitive : B
AR overexpression	Cholangiocarcinoma	AR overexpression	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D
NRAS Q61	Cholangiocarcinoma	NRAS Q61	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D
FGFR2 overexpression	Cholangiocarcinoma	FGFR2 overexpression	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D
FGFR1 overexpression	Cholangiocarcinoma	FGFR1 overexpression	Cholangiocarcinoma	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D	NXP800 Sensitive: D – Preclinical NXP800 Sensitive : D